Primary coronary intervention in acute myocardial infarction.
Percutaneous coronary intervention (PCI) with stent implantation has become the standard of care for acute myocardial infarction <12 hours from symptom onset. This has led to decreased morbidity and mortality both short and long term compared to thrombolytic therapy. Stent implantation has been demonstrated to be superior to balloon PCI for mechanical reperfusion of acute myocardial infarction. Intravenous antiplatelet glycoprotein IIb/IIIa inhibitors may have a role in improving TIMI flow prior to PCI and decreasing morbidity and mortality. The role of thrombolytics vs. IIb/IIIa inhibitors in "facilitated reperfusion" is unclear at this time and further research is needed to define the indication of adjunctive pharmacology.
Kim
Charles X
CX
Division of Cardiology, Department of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA.
Davidson
Charles J
CJ
D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D019917:Blood Vessel Prosthesis Implantation / Q000191:economics; D020099:Coated Materials, Biocompatible / Q000191:economics / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D005343:Fibrinolytic Agents / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000191:economics / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000191:economics; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000191:economics / Q000627:therapeutic use; D015607:Stents / Q000191:economics
D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex